- Conditions
- Alzheimer Disease, Mild Cognitive Impairment
- Interventions
- 2-hydroxybenzylamine acetate, Placebo
- Drug · Other
- Lead sponsor
- MTI Biotech Inc
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
Condition Directory
Alzheimer's Disease clinical trials
Directory of U.S. ClinicalTrials.gov public records for Alzheimer's Disease. Browse Alzheimer's Disease recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 24, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
2117
Shown on this page
12
Current sort
Recently updated
Condition scope
Alzheimer's Disease
Additional filters apply within this condition.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
How Alzheimer's Disease studies are organized in the registry
The registry typically spells this condition “Alzheimer disease” (without the apostrophe-s), and both spellings appear across listings. Early-stage research uses its own vocabulary — prevention and early-intervention studies are often filed under “mild cognitive impairment,” “prodromal,” or “preclinical” rather than the disease name, and some enroll cognitively healthy volunteers at elevated risk. This directory also has a dedicated mild cognitive impairment page.
Terms that often appear in related listings
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Showing 97–108 of 2,117 matching trials for Alzheimer's Disease.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Alzheimer Disease
- Interventions
- LY3439539
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 8
- States / cities
- Irvine, California • Long Beach, California • Los Angeles, California + 4 more
- Conditions
- Alzheimer Disease
- Interventions
- RB-ADSC
- Biological
- Lead sponsor
- Regeneration Biomedical, Inc.
- Industry
- Eligibility
- 45 Years to 80 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Alzheimer's Disease, Healthy Participants
- Interventions
- BMS-986446
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 6
- States / cities
- Anaheim, California • Bradenton, Florida • Daytona Beach, Florida + 3 more
- Conditions
- Dementia, Mild Cognitive Impairment (MCI), Cognitively Unimpaired, Alzheimer's Dementia (AD)
- Interventions
- Elemind Neuromodulation Headband, Exercise Routine
- Device · Other
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Alzheimer Disease
- Interventions
- High definition transcranial electrical current stimulation
- Device
- Lead sponsor
- Boston University Charles River Campus
- Other
- Eligibility
- 50 Years to 100 Years
- Enrollment
- 204 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Alzheimer Dementia (AD)
- Interventions
- IL-2 (Aldesleukin), Semaglutide Plus IL-2, Placebo
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 50 Years to 86 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Alzheimer Disease, Dementia
- Interventions
- tDCS device model Soterix mini-CT (Soterix Medical Inc., New York, NY) programed to deliver active tDCS., tDCS device model Soterix mini-CT (Soterix Medical Inc., New York, NY) programed to deliver sham tDCS.
- Device
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Mild Cognitive Impairment (MCI), Alzheimer Dementia (AD), Alzheimer Disease (AD), APOE-4 Positive
- Interventions
- Not listed
- Lead sponsor
- Prevention Research Consortium Corp.
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Alzheimer Disease
- Interventions
- KarXT, Placebo
- Drug
- Lead sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 406 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 102
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 71 more
- Conditions
- Dementia, Dementia, Vascular, Mixed Dementias, Alzheimer Disease, Huntington Disease, Lewy Body Disease, Creutzfeldt-Jakob Syndrome, Frontotemporal Lobar Degeneration, Cognitive Dysfunction, Cognitive Aging, Chronic Disease, Palliative Care, Patient Care, Health Care Quality, Access, and Evaluation, Patient Care, Health Communication, Patient Care Planning, Quality of Life
- Interventions
- Jumpstart Guide
- Behavioral
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,802 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Seattle, Washington
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment
- Interventions
- Placebo, Eligard 22.5Mg Suspension for Injection
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 60 Years to 120 Years · Female only
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 3
- States / cities
- Boca Raton, Florida • New York, New York • Madison, Wisconsin
About this Alzheimer's Disease clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Alzheimer's Disease as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Alzheimer's Disease.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Alzheimer's Disease.